In this CE activity, expert faculty review current and emerging treatment options for DME, DR, GA secondary to AMD, and other retinal diseases. They also assess the latest clinical trial data and real-world studies regarding the management of these conditions.
- Provider:Vindico Medical Education, LLC
- Activity Link: https://www.healio.com/cme/ophthalmology/20241023/the-retina-radar-with-dr-arshad-khanani-on-dr-ga-new-mechanisms-and-noninvasive-treatments/overview
- Start Date: 2024-10-31 05:00:00
- End Date: 2024-10-31 05:00:00
- Credit Details: AMA PRA Category 1 Credit™️: 1.0 hours
- Commercial Support: Source: AbbVie Inc. - Amount: 2500.0 - Is Kind Support: False Source: Alimera Sciences, Inc. - Amount: 625.0 - Is Kind Support: False Source: Apellis Pharmaceuticals, Inc. - Amount: 937.5 - Is Kind Support: False Source: Astellas - Amount: 1562.5 - Is Kind Support: False Source: EyePoint Pharmaceuticals, Inc. - Amount: 625.0 - Is Kind Support: False Source: Genentech, a member of the Roche Group - Amount: 4062.5 - Is Kind Support: False Source: Neurotech Pharmaceuticals, Inc. - Amount: 625.0 - Is Kind Support: False Source: Ocular Therapeutix, Inc. - Amount: 618.75 - Is Kind Support: False Source: Opthea - Amount: 937.5 - Is Kind Support: False Source: Regeneron Pharmaceuticals, Inc. - Amount: 4687.5 - Is Kind Support: False Source: REGENXBIO Inc. - Amount: 625.0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner Knowledge, Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
Subscribe
Login
0 Comments
Oldest